Opko Health (OPK) AI Stock Analysis
Opko Health
(TASE:OPK)
No summary available
Opko Health (OPK) vs. iShares MSCI Israel ETF (EIS)
- Market Cap
- ILS 1.24B
- Dividend Yield
- ―
- Average Volume (3M)
- 367.80K
- Price to Earnings (P/E)
- -17.0
- Beta (1Y)
- 0.28
- Revenue Growth
- -23.21%
- EPS Growth
- 64.08%
- Country
- Israel
- Employees
- 2,275
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Diagnostics & Research
Opko Health Business Overview & Revenue Model
Company Description
OPKO Health, Inc. operates as a healthcare enterprise with a dual focus on diagnostics and pharmaceuticals. Its operations span the United States, Ireland, Chile, Spain, Israel, Mexico, and other international markets. The company's Diagnostics divis...
Opko Health Earnings Call Summary
The call conveyed materially positive operational and financial momentum: substantial pipeline progress across ModeX and OPKO biologics, significant revenue growth in the Pharmaceutical segment, a stronger cash position (> $300M), improved consolidated results (much smaller net loss) and upgraded full-year revenue guidance. However, the company faces near-term headwinds including a year-over-year decline in diagnostics revenue tied to prior divestitures, elevated and persistent operating and R&D expenses, timing/reimbursement uncertainty for 4Kscore expansion, and clinical data/enrollment timing risks. Overall, the positive items (cash runway, pipeline advances, large revenue inflection items and much improved profitability metrics) outweigh the lowlights, but several execution and timing risks warrant monitoring.
Q2-2026 Updates
Positive Updates
Negative Updates
Company Guidance
OPKO guided Q3 2026 revenue of $131–142 million, including services revenue of $75–78 million, pharmaceutical product revenue of $40–44 million and IP & other revenue of $16–20 million (including Pfizer profit share of $8–10 million); Q3 total costs and expenses are expected to be $180–190 million with R&D of $34–38 million (partially offset by $5–7 million in BARDA and other collaboration funding) and depreciation & amortization of ~ $22 million. For full-year 2026 the company raised revenue guidance to $560–585 million (services $296–306 million; pharma product $164–174 million; partner collaboration/other $100–105 million, including Pfizer profit share $34–37 million), lowered total costs & expenses to $710–740 million, plans R&D of $125–135 million (offset by $18–22 million of BARDA funding and Regeneron reimbursements) and expects depreciation & amortization of ~ $95 million. The company also reported a Q2 cash balance of over $300 million, repurchased 9.7 million shares for ~ $13 million in the quarter and has approximately $94 million in remaining share repurchase authorization.
Opko Health Risk Analysis
Opko Health disclosed 54 risk factors in its most recent earnings report. Opko Health reported the most risks in the "Legal & Regulatory" category.
Latest Risks Added
0 New RisksOpko Health Peers Comparison
Overall Rating
CSTL70Outperform
NEO54Neutral
MYGN52Neutral
FLGT50Neutral
MDXH46Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| CSTL | 70Outperform | $1.14B | -56.34 | -4.15% | ― | 3.18% | -100.37% |
| NEO | 54Neutral | $2.25B | -70.42 | -3.97% | ― | 11.08% | 71.76% |
| MYGN | 52Neutral | $607.38M | -5.32 | -32.59% | ― | -3.16% | 72.02% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| FLGT | 50Neutral | $567.37M | -7.31 | -7.87% | ― | 6.83% | -69.59% |
| MDXH | 46Neutral | $15.58M | -0.28 | 142.63% | ― | 12.75% | 16.23% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| IL:OPK | Opko Health | 506.90 | 62.90 | 14.17% | |
| MYGN | Myriad Genetics | 6.35 | -1.83 | -22.37% | |
| NEO | NeoGenomics Inc. | 17.38 | 7.60 | 77.71% | |
| FLGT | Fulgent Genetics | 20.62 | -2.49 | -10.77% | |
| MDXH | Mdxhealth S.A. | 0.16 | -4.68 | -96.63% | |
| CSTL | Castle Biosciences | 37.16 | 11.17 | 42.98% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.